ZURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zura Bio Ltd (ZURA) is not a strong buy at this moment for a beginner investor with a long-term horizon. While the company has potential catalysts in its pipeline and recent fundraising efforts, its financial performance is weak, and the stock has no immediate trading signals. The current price trend and sentiment do not justify immediate action.
The stock shows a bullish trend with moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram. However, RSI is neutral at 64.982, and the stock is trading near the pivot level of 6.459. The short-term price trend suggests limited upside potential in the immediate future.
Zura Bio recently raised $144 million in a public offering to support its R&D efforts in autoimmune and inflammatory diseases. The company has also appointed experienced board members to enhance its clinical development strategy. Analysts have given an Outperform rating with a $15 price target, indicating potential long-term growth.
The stock has declined in both regular market (-0.66%) and pre-market (-2.95%) trading. Options data shows a bearish sentiment with a high Put-Call ratio (1.72 for open interest and 1.46 for volume). Financial performance is weak, with negative net income and EPS trends. No significant insider or hedge fund activity has been observed.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income drop of -12.66% YoY to -$20.037 million. EPS declined by -19.23% YoY to -0.21, indicating ongoing financial struggles.
Wedbush initiated coverage with an Outperform rating and a $15 price target, citing favorable near- and long-term setups. However, the stock's appreciation is tied to future clinical readouts, which may take 12-18 months.
